Cis-imidazolines

A compound selected from the group consisting of

• cis-4-[(4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-pyridin-3-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one,
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-pyridin-3-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-dimethyl-acetamide,
• cis-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-pyridin-3-yl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone,
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2-ethoxy-pyridin-3-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone,
• cis-4-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-trifluoromethyl-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one,
• cis-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-trifluoromethyl-pyrimidin-5-yl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone,
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-trifluoromethyl-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone,
• cis-4-[4,5-Bis-(4-chloro-phenyl)-2-(2,4-diethoxy-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one,
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2,4-diethoxy-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-dimethyl-acetamide,
• cis-[4,5-Bis-(4-chloro-phenyl)-2-(2,4-diethoxy-pyrimidin-5-yl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone,
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(2,4-diethoxy-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone,
• cis-4-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-methylsulfanyl-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one and
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-methylsulfanyl-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-dimethyl-acetamide.

A compound selected from the group consisting of

• cis-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-methylsulfanyl-pyrimidin-5-yl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone,
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-methylsulfanyl-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone,
• cis-4-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-methyl-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one,
• cis-2-(4-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-methyl-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-dimethyl-acetamide,
• cis-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-methyl-pyrimidin-5-yl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone,
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(4-ethoxy-2-methyl-pyrimidin-5-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone,
• cis-4-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one hydrochloride,
• cis-2-{4-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-dimethyl-acetamide hydrochloride,
• cis-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone hydrochloride,
• cis-2-{4-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone,
• cis-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-dimethylamino-piperidin-1-yl)-methanone,
• cis-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-pyrrolidin-1-yl-piperidin-1-yl)-methanone and
• cis-1-{4-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-ethanone.

A compound selected from the group consisting of

• cis-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazol-1-yl]-(4-methyl-piperazin-1-yl)-methanone,
• cis-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(3-methanesulfonyl-propyl)-piperazin-1-yl]-methanone,
• cis-[2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazol-1-yl]-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-methanone,
• 2-{4-[(4S,5R)-2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone,
• 4-[(4S,5R)-2-(2-tert-Butyl-4-ethoxy-pyrimidin-5-yl)-4,5-bis-(4-chloro-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one,
• cis-4-[4,5-Bis-(4-chloro-phenyl)-2-(4,6-diethoxy-pyridin-3-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one hydrochloride,
• cis-[4,5-Bis-(4-chloro-phenyl)-2-(4,6-diethoxy-pyridin-3-yl)-4,5-dihydro-imidazol-1-yl]-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-methanone hydrochloride,
• 2-{4-[(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-tert-butyl-acetamide,
• 2-{4-[(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-acetamide,
• 2-{4-[(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N,N-bis-(2-methoxy-ethyl)-acetamide,
• 2-{4-[(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-methoxy-N-methyl-acetamide,
• 2-{4-[(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-isopropyl-N-methyl-acetamide,
• 2-{4-[(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-cyano-ethyl)-N-methyl-acetamide,
• cis-2-{4-[4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-N-(2-methoxy-1-methyl-ethyl)-acetamide and
• [(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazol-1-yl]-[4-(3,5-dimethyl-isoxazole-4-carbonyl)-piperazin-1-yl]-methanone.

A compound selected from the group consisting of

• [(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazol-1-yl]-(4-ethanesulfonyl-piperazin-1-yl)-methanone,
• N-(2-{4-[(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}ethyl)-methanesulfonamide,
• [(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazol-1-yl]-[4-(3-methanesulfonyl-propyl)-piperazin-1-yl]-methanone,
• [(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazol-1-yl]-[4-(2-methanesulfonyl-ethyl)-piperazin-1-yl]-methanone and
• 2-{4-[(4S,5R)-4,5-Bis-(4-chloro-phenyl)-2-(3-ethoxy-thiophen-2-yl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-1-yl}-1-morpholin-4-yl-ethanone.

A method of treating a disease based on the interaction of MDM2 protein with a p53-like peptide comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula I

• and the pharmaceutically acceptable salts and esters thereof, wherein
• Ring A is:
• X1 is selected from the group consisting of
• lower alkoxy, and
• lower alkoxy substituted by trifluoromethyl or fluorine;
• X2 is selected from the group consisting of
• hydrogen,
• thioalkyl,
• lower alkyl,
• lower alkoxy,
• morpholino, and
• —NX3X4;
• X3 and X4 are independently selected from the group consisting of
• hydrogen,
• lower alkyl,
• lower alkyl substituted by lower alkoxy or cyano, and
• lower alkoxy;
• Y and Z are independently selected from the group consisting of:
• carbon, and
• nitrogen;
• V1 and V2 are independently selected from the group consisting of
• halogen,
• cyano, and
• acetylene;
• R is selected from the group consisting of
• piperidinyl substituted by five or six membered heterocycle,
• piperidinyl substituted by —NX3X4, and
• wherein
• n=1 or 2,
• R1 can be one or more substituents selected from the group consisting of
• hydrogen,
• oxo,
• lower alkyl substituted by R2,
• —C(O)R3, and
• —SO2-lower alkyl;
• R2 is selected from the group consisting of
• hydroxy,
• lower alkoxy,
• trifluoromethyl,
• -cyano,
• —NH—SO2-lower alkyl,
• —NH—C(O)-lower alkyl,
• —C(O)-lower alkyl,
• —C(O)R4,
• —C(O)—NX3X4,
• —SO2-lower alkyl,
• —SO2—NX3X4,
• R3 is selected from the group consisting of
• five membered heterocycle,
• lower alkyl,
• lower alkoxy, and
• lower alkyl substituted by lower alkoxy and
• R4 is selected from the group consisting of
• hydroxy,
• lower alkoxy,
• morpholino, and
• —NX3X4.

A pharmaceutical composition comprising a compound of the formula I

• and the pharmaceutically acceptable salts and esters thereof, wherein
• Ring A is:
• X1 is selected from the group consisting of
• lower alkoxy, and
• lower alkoxy substituted by trifluoromethyl or fluorine;
• X2 is selected from the group consisting of
• hydrogen,
• thioalkyl,
• lower alkyl,
• lower alkoxy,
• morpholino, and
• —NX3X4;
• X3 and X4 are independently selected from the group consisting of
• hydrogen,
• lower alkyl,
• lower alkyl substituted by lower alkoxy or cyano, and
• lower alkoxy;
• Y and Z are independently selected from the group consisting of:
• carbon, and
• nitrogen;
• V1 and V2 are independently selected from the group consisting of
• halogen,
• cyano, and
• acetylene;
• R is selected from the group consisting of
• piperidinyl substituted by five or six membered heterocycle,
• piperidinyl substituted by —NX3X4, and
• wherein
• n=1 or 2,
• R1 can be one or more substituents selected from the group consisting of
• hydrogen,
• oxo,
• lower alkyl substituted by R2,
• —C(O)R3, and
• —SO2-lower alkyl;
• R2 is selected from the group consisting of
• hydroxy,
• lower alkoxy,
• trifluoromethyl,
• -cyano,
• —NH—SO2-lower alkyl,
• —NH—C(O)-lower alkyl,
• —C(O)-lower alkyl,
• —C(O)R4,
• —C(O)—NX3X4,
• —SO2-lower alkyl,
• —SO2—NX3X4,
• R3 is selected from the group consisting of
• five membered heterocycle,
• lower alkyl,
• lower alkoxy, and
• lower alkyl substituted by lower alkoxy and
• R4 is selected from the group consisting of
• hydroxy,
• lower alkoxy,
• morpholino, and
• —NX3X4
• and a pharmaceutically acceptable carrier.